EMIS is a clinical software supplier to the primary, community and acute care markets in the UK and provides software to the community pharmacy market. Its Patient business provides medical and wellbeing information as well as transactional services to patients.
TMT |
Flash note
TMT |
Flash note
TMT |
Flash note
TMT |
Update
% | 1M | 3M | 12M |
---|---|---|---|
Actual | (0.6) | 32.2 | 3.3 |
Relative | 3.7 | 40.4 | 1.3 |
52 week high/low | 1934.0p/1310.0p |
Edison Investment Research is terminating coverage on Kinarus Therapeutics (KNRS), Numis Corporation (NUM), EMIS Group (EMIS), Pixium Vision (PIX) and Treatt (TET). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via website
Y/E Dec | Revenue (£m) | EBITDA (£m) | PBT (£m) | EPS (fd) (p) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2021A | 168.2 | 54.7 | 43.5 | 55.0 | 34.9 | 24.2 |
2022A | 175.4 | 59.4 | 48.1 | 60.9 | 31.5 | 24.8 |
2023E | N/A | N/A | N/A | N/A | N/A | N/A |
2024E | N/A | N/A | N/A | N/A | N/A | N/A |